

Taddle Creek

MEDICAL DIRECTIVE

Family Health Team

Title:	Fecal Occult Blood Test	Number:	TCFHT-MD01
Activation Date:	01-January-2014	Review Date:	08-October-2017
Next Review Date:	08-October-2018		
Sponsoring/Contact	Dr. Mira Barman		
Person(s)	790 Bay St. Suite 302		
(name, position,	Toronto, ON M5G 1N8		
contact particulars):	416-585-9555		
	Vicki McGregor, RN		
	790 Bay St. Suite 302		
	Toronto, ON M5G 1N8		
	416-585-9555		
	Sherry Kennedy, Executive	Director - skennedy@	atefat on ca
	790 Bay Street, Suite 306	Director <u>skernicaye</u>	<u>& territ.orr.ca</u>
	Toronto, Ontario M5G 1N8	₹	
	416-260-1315, x307	,	
	0 _00 _0_0,		
Order and/or Delegat	ed Procedure:	Appendix Attached:	☐ Yes ☑ No
Implementers may ord	er a Fecal Occult Blood Test	(FOBT) for colorectal o	cancer (CRC) screening in
accordance with the co	onditions identified in this dir	ective.	
Recipient Patients:		• •	☑ Yes □No
Da sinia nta manata	L	Title: Appendix A – Autho	orizer Approval Form
Recipients must:	f - TCCUT - i	:	d this discosting by significan
•	of a TCFHT primary care prov	ider who has approve	a this directive by signing
the Authorizer App			
Be 50 to 74 years or Most the condition	_	al cancar as identifie	d in this directive
Meet the condition	s of average risk for colorect	ai cancer, as identine	a in this directive
* Fligible if they are 49	years old and their 50 th birth	nday is within 60 days	of application of the
directive	, 55.0 0.5 6.15 6.15 0.0	, is maini so days	o. approacion or the
Authorized Implemen	nters:	Appendix Attached:	☑ Yes □No
		1	lementer Approval Form

Implementer must be a TCFHT employed Regulated Health Care Provider or Physician Assistant (under the supervision of a physician).

Implementers must have completed the following training and sign the Implementer Approval Form:

- Review the entire Health Care Professionals section of the Ontario Ministry of Health and Long Term Care ColonCancerCheck program website, accessible from: http://health.gov.on.ca/en/pro/programs/coloncancercheck/
- Review the following Cancer Care Ontario articles:
 - a. Cancer Care Ontario. (2016). *Screening Guidelines Colon Cancer*, accessible from: https://www.cancercare.on.ca/pcs/screening/coloscreening/cccstandardsguidelines/
 - b. Cancer Care Ontario. (2016). *About ColonCancerCheck,* accessible from: https://www.cancercare.on.ca/pcs/screening/coloscreening/cccworks/
- Review the following articles, accessible from http://www.UptoDate.com:
 - a. Doubeni, C. (2017). Screening for colorectal cancer: Strategies in patients at average risk.
 - b. Doubeni, C. (2017). *Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy.*

Indications:	Appendix Attached: ☑ Yes ☐ No
	Title: Appendix C – CRC (FOBT) Screening Requisition

Implementers may order a ColonCancerCheck FOBT for eligible patients who are 50 to 74 years old* who are at average risk of CRC. Implementers may order the FOBT using a Ministry of Health and Long-Term Care Laboratory Requisition.

Average Risk (eligible for FOBT):

- Patients age 50-74 with no first-degree relatives who have been diagnosed with CRC (Cancer Care Ontario, 2016).
- No personal history of pre-cancerous colorectal polyps requiring surveillance (Cancer Care Ontario, 2016).
- No personal history of inflammatory bowel disease (i.e., ulcerative colitis or Crohn's disease) (Cancer Care Ontario, 2016).

Increased Risk (not eligible for FOBT):

- Patients who have a personal history of CRC (Cancer Care Ontario, 2016).
- Patients who have a family history that includes one or more first-degree relatives who have been diagnosed with CRC (Cancer Care Ontario, 2016).
- Patients with a personal history of pre-cancerous colorectal polyps requiring surveillance (Cancer Care Ontario, 2016)
- Patients who have a personal history of inflammatory bowel disease (i.e., ulcerative colitis or Crohn's disease) (Cancer Care Ontario, 2016).
- Patients who have average risk for CRC and have a normal colonoscopy on file within the last 10 years (Doubeni, 2017).
- * Eligible if they are 49 years old and their 50th birthday is within 60 days of application of the directive

TCFHT-MD01	Fecal	Occult	Blood	Test
I CI I I I IVIDOT	i ccui	Occur	DIOCG	1 0 3 0

Consent:	Appendix Attached: ☑ Yes ☐ No						
	Title: Appendix D – Turning 50 CRC Screening (FOBT) Letter						
The patient has enrolled with their provider at the							
health information and notification of screening el							
FOBT kit in the mail, which will encourage the patie							
questions. Once receiving the FOBT kit in the mail, the patient completes the test by his or her own							
volition. At the 30-60-day follow up reminder call,	the implementer will discuss the FOBT kit with the						
patient and if they do not consent to the screening	, it will be noted to their EMR for future						
reference.							
Guidelines for Implementing the	Appendix Attached: ☐ Yes ☑ No						
Order/Procedure:	TCFUT nationts' access to CDC servening which is						
in accordance with provincial cancer screening gui	e TCFHT patients' access to CRC screening, which is						
Breast, Cervical, & Colorectal Cancer Screening" (C							
Diedot, del vida, di dolor edial dandel dol delimig	ander care emaile, 2020).						
Documentation and Communication:	Appendix Attached: ☐ Yes ☑ No						
·	ved an eligible patient's EMR and ordered an FOBT						
using the "Turning 50 CRC (FOBT) Screening Progra	am" Encounter Assistant custom form.						
The implementer will send a message in Practice S	·						
indicating that they have ordered an FOBT for the	patient.						
The implementer will send a delayed message to the	hemselves in 60 days to follow up with the patient						
via phone if the FOBT test is not completed within	·						
call, no further follow up is required.	эт э						
•							
Review and Quality Monitoring Guidelines	Appendix Attached: ☐ Yes ☑ No						

- Routine review will occur annually on the anniversary of the activation date. Review will involve a collaboration between the authorizing primary care providers and the approved implementers.
- If new information becomes available between routine reviews, such as the publishing of new
 clinical practice guidelines, and particularily if this new information has implications for
 unexpected outcomes, the directive will be reviewed by an authorizing primary care provider
 and a mimimum of one implementer
- At any such time that issues related to the use of this directive are identified, TCFHT must act
 upon the concerns and immediately undertake a review of the directive by the authorizing
 primary care providers and the authorized implementers.
- This medical directive can be placed on hold if routine review processes are not completed, or if
 indicated for an ad hoc review. During the hold, implementers cannot perform the procedures
 under authority of the directive and must obtain direct, patient-specific orders for the procedure
 until it is renewed.

References:

- Cancer Care Ontario. (2016). *Cancer screening guidelines for breast, cervical, & colorectal cancer screening*. Retrieved from
 - https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=273767
- Cancer Care Ontario. (2016). About ColonCancerCheck. Retrieved from
 - https://www.cancercare.on.ca/pcs/screening/coloscreening/cccworks/
- Cancer Care Ontario. (2016). *Screening Guidelines Colon Cancer Check.* Retrieved from https://www.cancercare.on.ca/pcs/screening/coloscreening/cccstandardsguidelines/
- Doubeni, C. (2017). Screening for colorectal cancer: Strategies in patients at average risk.

 Retrieved from http://www.uptodate.com
- Doubeni, C. (2017). *Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy.* Retrieved from http://www.uptodate.com

NOTE:

This medical directive is based on TCFHT's previous medical directive PH-1 entitled, "Preventive Health," which required revision in formatting to reflect the growth of the TCFHT organization. The majority of the content of PH-1 has remained the same for the revised TCFHT-MD01 version. Therefore, all approved Implementers and Authorizers for medical directive PH-1 "Preventive Health" have grandfathered approval for TCFHT-MD01 "Fecal Occult Blood Test."

Appendix A:

Authorizer Approval Form

Name	Signature	Date
	-	
		
		· · · · · · · · · · · · · · · · · · ·
		

Appendix B:

Implementer Approval Form

To be signed when the implementer has completed the required preparation, and feel they have the knowledge, skill, and judgement to competently carry out the actions outlined in this directive.

Name	Signature	Date
		

Appendix C:

Preventive Health – CRC Screening Requisition

Ontario Ministry of Health and Long-Term Care Laboratory Requisition Requisitioning Clinician / Practitioner Name		Lab	oratory Üse Önly						
Trudy Chernin									
Address									
790 Bay Street									
	ronto, ON			Clin	ician/Practitioner's Contact Number for Urge	ent Results	e .	Service Date	
	5G 1N8			, ,	·	Jill Hoodilo	,	yyyy Service Date mm dd	
Clin	ician/Practitioner Number	CPS	O / Registration No.	(416) 960-1366 Health Number Version			Sex Date of Birth		
271858				VOISION		yyyy mm dd			
Check (ν) one:		_	Vince Other Provincial Registration Number	<u> </u>	⊠ M	F 1930 10 11 Patient's Telephone Contact Number			
M OHIP/Insured ☐ Third Party / Uninsured ☐ WSIB			(416) 555-5555						
	ditional Clinical Information (e.g. diagno			Pati	ent's Last Name (as per OHIP Card)			(410 / 555-5555	
	. 5	,		Du	ck				
				_	ent's First & Middle Names (as per OHIP Co	ard)			
					nald	*			
Н	Copy to: Clinician/Practitioner			-	ent's Address (including Postal Code)				
	t Name: First	Name	e						
					7 Bay Street ronto, ON				
Add	ress				N 5J5				
				' '	14 000				
No	te: Separate requisitions are re	equii	red for cytology, his	stole	ngy / pathology and tests performed	d by Pub	lic He	alth Laboratory	
x	Biochemistry			x	Hematology		x v	iral Hepatitis (check one only)	
	Glucose Random	n	Fasting		CBC		Α	cute Hepatitis	
	HbA1C				Prothrombin Time (INR)		C	chronic Hepatitis	
	TSH				Immunology			mmune Status / Previous Exposure	
	Creatinine (eGFR)			Pregnancy test (Urine) Specify.		Specify: ☐ Hepatitis A ☐ Hepatitis B			
	Uric Acid			Mononucleosis Screen			Hepatitis C or order individual hepatitis tests in the "Other Tests" section below		
	Sodium			Rubella		0			
	Potassium			-	Prenatal: ABO, RhD, Antibody Screen (titre and ident. if positive)	-			
	Chloride						Prostate Specific Antigen (PSA)		
	CK ALT			Repeat Prenatal Antibodies			☐ Total PSA ☐ Free PSA Specify one below: ☐ Insured – Meets OHIP eligibility criteria		
	Alk. Phosphatase			Microbiology ID & Sensitivities (if warranted)					
				Cervical			Uninsured – Screening: Patient responsible for payment		
	Albumin	Bilirubin							
					Vaginal	_		in D (25-Hydroxy)	
Lipid Assessment (includes Cholesterol, HDL-C, Triglycerides, calculated LDL-C & Chol/HDL-C ratio; individual lipid tests may		erol, l	HDL-C, Triglycerides,				Vitam	in D (25-Hydroxy)	
		erol, l io; inc ion of	HDL-C, Triglycerides, dividual lipid tests may this form)		Vaginal		Vitam	in D (25-Hydroxy) ured – Meets OHIP eligibility criteria: osteopenia; osteoporosis; rickets; renal disease; malabsorption syndromes;	
	Lipid Assessment (includes Choleste calculated LDL-C & Chol/HDL-C rati	erol, I io; inc ion of	HDL-C, Triglycerides, lividual lipid tests may this form)		Vaginal Vaginal / Rectal – Group B Strep		Vitam Ins	in D (25-Hydroxy) ured – Meets OHIP eligibility criteria: osteopenia; osteoporosis; rickets; renal disease; malabsorption syndromes; medications affecting vitamin D metabolism	
	Lipid Assessment (includes Cholest calculated LDL-C & Chol/HDL-C rati be ordered in the "Other Tests" secti Vitamin B12 Ferritin	erol, I io; inc ion of	HDL-C, Triglycerides, dividual lipid tests may this form)		Vaginal Vaginal / Rectal – Group B Strep Chlamydia (specify source): GC (specify source): Sputum		Vitam Ins	in D (25-Hydroxy) ured – Meets OHIP eligibility criteria: osteopenia; osteoporosis; rickets; renal disease; malabsorption syndromes;	
	Lipid Assessment (includes Cholest calculated LDL-C & Chol/HDL-C rati be ordered in the "Other Tests" secti Vitamin B12 Ferritin Albumin / Creatinine Ratio, Urine	erol, I io; inc ion of	HDL-C, Triglycerides, lividual lipid tests may this form)		Vaginal Vaginal / Rectal – Group B Strep Chlamydia (specify source): GC (specify source): Sputum Throat		Vitam Ins	in D (25-Hydroxy) ured – Meets OHIP eligibility criteria: osteopenia; osteoporosis; rickets; renal disease; malabsorption syndromes; medications affecting vitamin D metabolism	
	Lipid Assessment (includes Cholest calculated LDL-C & Chol/HDL-C rati be ordered in the "Other Tests" secti Vitamin B12 Ferritin Albumin / Creatinine Ratio, Urine Urinalysis (Chemical)	erol, I io; inc ion of	HDL-C, Triglycerides, lividual lipid tests may this form)		Vaginal Vaginal / Rectal – Group B Strep Chlamydia (specify source): GC (specify source): Sputum Throat Wound (specify source):		Vitam Ins	in D (25-Hydroxy) ured – Meets OHIP eligibility criteria: osteopenia; osteoporosis; rickets; renal disease; malabsorption syndromes; medications affecting vitamin D metabolism nsured – Patient responsible for payment	
	Lipid Assessment (includes Cholest calculated LDL-C & Chol/HDL-C rati be ordered in the "Other Tests" secti Vitamin B12 Ferritin Albumin / Creatinine Ratio, Urine Urinalysis (Chemical) Neonatal Bilirubin:	ion of	this form)		Vaginal Vaginal / Rectal – Group B Strep Chlamydia (specify source): GC (specify source): Sputum Throat Wound (specify source): Urine		Vitam Ins	in D (25-Hydroxy) ured – Meets OHIP eligibility criteria: osteopenia; osteoporosis; rickets; renal disease; malabsorption syndromes; medications affecting vitamin D metabolism nsured – Patient responsible for payment	
	Lipid Assessment (includes Cholest calculated LDL-C & Chol/HDL-C rati be ordered in the "Other Tests" secti Vitamin B12 Ferritin Albumin / Creatinine Ratio, Urine Urinalysis (Chemical) Neonatal Bilirubin: Child's Age: days	s	HDL-C, Triglycerides, lividual lipid tests may this form)		Vaginal Vaginal / Rectal – Group B Strep Chlamydia (specify source): GC (specify source): Sputum Throat Wound (specify source): Urine Stool Culture		Vitam Ins	in D (25-Hydroxy) ured – Meets OHIP eligibility criteria: osteopenia; osteoporosis; rickets; renal disease; malabsorption syndromes; medications affecting vitamin D metabolism nsured – Patient responsible for payment	
	Lipid Assessment (includes Cholest calculated LDL-C & Chol/HDL-C rati be ordered in the "Other Tests" secti Vitamin B12 Ferritin Albumin / Creatinine Ratio, Urine Urinalysis (Chemical) Neonatal Bilirubin: Child's Age: days Clinician/Practitioner's tel. no. (ion of	this form)		Vaginal Vaginal / Rectal – Group B Strep Chlamydia (specify source): GC (specify source): Sputum Throat Wound (specify source): Urine Stool Culture Stool Ova & Parasites		Vitam Ins	in D (25-Hydroxy) ured – Meets OHIP eligibility criteria: osteopenia; osteoporosis; rickets; renal disease; malabsorption syndromes; medications affecting vitamin D metabolism nsured – Patient responsible for payment	
	Lipid Assessment (includes Cholest calculated LDL-C & Chol/HDL-C rati be ordered in the "Other Tests" secti Vitamin B12 Ferritin Albumin / Creatinine Ratio, Urine Urinalysis (Chemical) Neonatal Bilirubin: Child's Age: days Clinician/Practitioner's tel. no. (Patient's 24 hr telephone no. (s	this form)		Vaginal Vaginal / Rectal – Group B Strep Chlamydia (specify source): GC (specify source): Sputum Throat Wound (specify source): Urine Stool Culture		Vitam Ins	in D (25-Hydroxy) ured – Meets OHIP eligibility criteria: osteopenia; osteoporosis; rickets; renal disease; malabsorption syndromes; medications affecting vitamin D metabolism nsured – Patient responsible for payment	
	Lipid Assessment (includes Cholest calculated LDL-C & Chol/HDL-C ration be ordered in the "Other Tests" sectivitamin B12 Ferritin Albumin / Creatinine Ratio, Urine Urinalysis (Chemical) Neonatal Bilirubin: Child's Age: days Clinician/Practitioner's tel. no. (Patient's 24 hr telephone no. (Therapeutic Drug Monitoring:	s	this form)	Spe	Vaginal Vaginal / Rectal – Group B Strep Chlamydia (specify source): GC (specify source): Sputum Throat Wound (specify source): Urine Stool Culture Stool Ova & Parasites		Vitam Ins	in D (25-Hydroxy) ured – Meets OHIP eligibility criteria: osteopenia; osteoporosis; rickets; renal disease; malabsorption syndromes; medications affecting vitamin D metabolism nsured – Patient responsible for payment	
	Lipid Assessment (includes Cholest calculated LDL-C & Chol/HDL-C rati be ordered in the "Other Tests" secti Vitamin B12 Ferritin Albumin / Creatinine Ratio, Urine Urinalysis (Chemical) Neonatal Bilirubin: Child's Age: days Clinician/Practitioner's tel. no. (Patient's 24 hr telephone no. (s	this form)	Spo	Vaginal Vaginal / Rectal – Group B Strep Chlamydia (specify source): GC (specify source): Sputum Throat Wound (specify source): Urine Stool Culture Stool Ova & Parasites Other Swabs / Pus (specify source):		Vitam Ins	in D (25-Hydroxy) ured – Meets OHIP eligibility criteria: osteopenia; osteoporosis; rickets; renal disease; malabsorption syndromes; medications affecting vitamin D metabolism nsured – Patient responsible for payment	
	Lipid Assessment (includes Choleste calculated LDL-C & Chol/HDL-C ration be ordered in the "Other Tests" sectivitamin B12 Ferritin Albumin / Creatinine Ratio, Urine Urinalysis (Chemical) Neonatal Bilirubin: Child's Age: days Clinician/Practitioner's tel. no. (Patient's 24 hr telephone no. (Therapeutic Drug Monitoring: Name of Drug #1 Name of Drug #2	s	this form)	Tin	Vaginal Vaginal / Rectal – Group B Strep Chlamydia (specify source): GC (specify source): Sputum Throat Wound (specify source): Urine Stool Culture Stool Culture Stool Ova & Parasites Other Swabs / Pus (specify source):		Vitam Ins	in D (25-Hydroxy) ured – Meets OHIP eligibility criteria: osteopenia; osteoporosis; rickets; renal disease; malabsorption syndromes; medications affecting vitamin D metabolism nsured – Patient responsible for payment	
	Lipid Assessment (includes Choleste calculated LDL-C & Chol/HDL-C ration be ordered in the "Other Tests" sectivitamin B12 Ferritin Albumin / Creatinine Ratio, Urine Urinalysis (Chemical) Neonatal Bilirubin: Child's Age: days Clinician/Practitioner's tel. no. (Patient's 24 hr telephone no. (Therapeutic Drug Monitoring: Name of Drug #1 Name of Drug #2 Time Collected #1	s)	hours	Fe	Vaginal Vaginal / Rectal – Group B Strep Chlamydia (specify source): GC (specify source): Sputum Throat Wound (specify source): Urine Stool Culture Stool Culture Stool Ova & Parasites Other Swabs / Pus (specify source): ceimen Collection 10 24 hour clock Date Symmotic Collection 11 24 hour clock Cal Occult Blood Test (FOBT) (chec	//dd	Vitam Ins Uni Other	in D (25-Hydroxy) ured – Meets OHIP eligibility criteria: osteopenia; osteoporosis; rickets; renal disease; malabsorption syndromes; medications affecting vitamin D metabolism nsured – Patient responsible for payment	
	Lipid Assessment (includes Choleste calculated LDL-C & Chol/HDL-C ration be ordered in the "Other Tests" sectivitiamin B12 Ferritin Albumin / Creatinine Ratio, Urine Urinalysis (Chemical) Neonatal Bilirubin: Child's Age: Clinician/Practitioner's tel. no. (Patient's 24 hr telephone no. (Therapeutic Drug Monitoring: Name of Drug #1 Name of Drug #2 Time Collected #1 Time of Last Dose #1	s)	hours hours #2 hr.	Fe	Vaginal Vaginal / Rectal – Group B Strep Chlamydia (specify source): GC (specify source): Sputum Throat Wound (specify source): Urine Stool Culture Stool Culture Stool Ova & Parasites Other Swabs / Pus (specify source): ceimen Collection 10 24 hour clock Date Symmotic Collection 11 24 hour clock Cal Occult Blood Test (FOBT) (chec	//dd	Vitam Ins Uni Other	in D (25-Hydroxy) ured – Meets OHIP eligibility criteria: osteopenia; osteoporosis; rickets; renal disease; malabsorption syndromes; medications affecting vitamin D metabolism nsured – Patient responsible for payment Tests – one test per line	
	Lipid Assessment (includes Cholesticalculated LDL-C & Chol/HDL-C ratible ordered in the "Other Tests" sectivitiamin B12 Ferritin Albumin / Creatinine Ratio, Urine Urinalysis (Chemical) Neonatal Bilirubin: Child's Age: days Clinician/Practitioner's tel. no. (Patient's 24 hr telephone no. (Therapeutic Drug Monitoring: Name of Drug #1 Name of Drug #2 Time Collected #1 Time of Last Dose #1 Time of Next Dose #1 Intereby certify the tests ordered are interesting the content of the case of t	hr. hr. hr.	#2 hr. #2 hr. #2 hr. #2 hr.	Fe	Vaginal Vaginal / Rectal – Group B Strep Chlamydia (specify source): GC (specify source): Sputum Throat Wound (specify source): Urine Stool Culture Stool Ova & Parasites Other Swabs / Pus (specify source): ceimen Collection 10 24 hour clock Cal Occult Blood Test (FOBT) (chec	//dd	Vitam Ins Uni Other	in D (25-Hydroxy) ured – Meets OHIP eligibility criteria: osteopenia; osteoporosis; rickets; renal disease; malabsorption syndromes; medications affecting vitamin D metabolism nsured – Patient responsible for payment Tests – one test per line	
O	Lipid Assessment (includes Cholesticalculated LDL-C & Chol/HDL-C ratible ordered in the "Other Tests" sectivitiamin B12 Ferritin Albumin / Creatinine Ratio, Urine Urinalysis (Chemical) Neonatal Bilirubin: Child's Age: days Clinician/Practitioner's tel. no. (Patient's 24 hr telephone no. (Therapeutic Drug Monitoring: Name of Drug #1 Name of Drug #2 Time Collected #1 Time of Last Dose #1 Time of Next Dose #1	hr. hr. hr.	#2 hr. #2 hr. #2 hr. #2 hr.	Fe	Vaginal Vaginal / Rectal – Group B Strep Chlamydia (specify source): GC (specify source): Sputum Throat Wound (specify source): Urine Stool Culture Stool Ova & Parasites Other Swabs / Pus (specify source): ceimen Collection 10 24 hour clock Cal Occult Blood Test (FOBT) (chec	//dd	Vitam Ins Uni Other	in D (25-Hydroxy) ured – Meets OHIP eligibility criteria: osteopenia; osteoporosis; rickets; renal disease; malabsorption syndromes; medications affecting vitamin D metabolism nsured – Patient responsible for payment Tests – one test per line	
O	Lipid Assessment (includes Choleste calculated LDL-C & Chol/HDL-C ration be ordered in the "Other Tests" sectivitiamin B12 Ferritin Albumin / Creatinine Ratio, Urine Urinalysis (Chemical) Neonatal Bilirubin: Child's Age: days Clinician/Practitioner's tel. no. (Patient's 24 hr telephone no. (Therapeutic Drug Monitoring: Name of Drug #1 Name of Drug #2 Time Collected #1 Time of Last Dose #1 Time of Next Dose #1 Tereby certify the tests ordered are in the patients of a hospital.	hr. hr. hr.	#2 hr. #2 hr. #2 hr. #2 hr.	Fe	Vaginal Vaginal / Rectal – Group B Strep Chlamydia (specify source): GC (specify source): Sputum Throat Wound (specify source): Urine Stool Culture Stool Ova & Parasites Other Swabs / Pus (specify source): ceimen Collection 10 24 hour clock Cal Occult Blood Test (FOBT) (chec	//dd	Vitam Ins Uni Other	in D (25-Hydroxy) ured – Meets OHIP eligibility criteria: osteopenia; osteoporosis; rickets; renal disease; malabsorption syndromes; medications affecting vitamin D metabolism nsured – Patient responsible for payment Tests – one test per line	
о М <u>х</u>	Lipid Assessment (includes Choleste calculated LDL-C & Chol/HDL-C ration be ordered in the "Other Tests" sectivitiamin B12 Ferritin Albumin / Creatinine Ratio, Urine Urinalysis (Chemical) Neonatal Bilirubin: Child's Age: days Clinician/Practitioner's tel. no. (Patient's 24 hr telephone no. (Therapeutic Drug Monitoring: Name of Drug #1 Name of Drug #2 Time Collected #1 Time of Last Dose #1 Time of Next Dose #1 Tereby certify the tests ordered are in the patients of a hospital.	hr. hr.	#2 hr. #2 hr. #2 hr. #2 hr.	Fe	Vaginal Vaginal / Rectal – Group B Strep Chlamydia (specify source): GC (specify source): Sputum Throat Wound (specify source): Urine Stool Culture Stool Ova & Parasites Other Swabs / Pus (specify source): ceimen Collection 10 24 hour clock Cal Occult Blood Test (FOBT) (chec	//dd	Vitam Ins Uni Other	in D (25-Hydroxy) ured – Meets OHIP eligibility criteria: osteopenia; osteoporosis; rickets; renal disease; malabsorption syndromes; medications affecting vitamin D metabolism nsured – Patient responsible for payment Tests – one test per line	

4422-84 (2010/09) © Queen's Printer for Ontario, 2010

7530-4581

Appendix D:

Turning 50 CRC Screening (FOBT) Letter

Implementer Name

Implementer Taddle Creek FHT Contact Information Date Dear Patient's First Name, I am the Registered Nurse that works with your primary care provider. Our records show that you will soon be turning 50 years old. Happy Birthday! This is an important milestone in your life and an opportunity to focus on your health. As part of your primary care team, I'm committed to helping you be as healthy as possible. A key part of maintaining your health is the prevention and screening of chronic diseases. Our records show that you are due for colorectal cancer screening: Colorectal Cancer Screening – Adults aged 50 to 74 are encouraged to do the Fecal Occult Blood Test (FOBT) every 2 years. I have included an FOBT kit in this package. Please review the instructions, do the FOBT test as soon as you can, and pop the kit in the mail when you're done. FOBT has been found to decrease the risk of dying from colorectal cancer. A person with colorectal cancer has a 90% chance of being cured if the cancer is caught early with screening. Go to www.youtube.com and search "Home Screening for Colon Cancer (FOBT)" for more details. Note: If you have a personal or family history of colorectal cancer, FOBT screening may not be appropriate. In this case, please contact us to discuss what screening is recommended for you. If in 2 months we have not received your FOBT results, I will call you to follow up. As part of your primary care team, I appreciate the opportunity to work with you to enhance your health and prevent illness. Should you have any questions or concerns, feel free to contact me. Yours truly, Implementer Name and Signature